Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Becton, Dickinson and Company BDX

Healthcare  —  Medical Instruments & Supplies
183.82 4.59 2.56% as of 25 Sep
Market cap
$48.8B
P/E
55.4×
S&P 500 Member Dividend Aristocrat Revenue Champion (3y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Becton, Dickinson and Company (BDX) Business Profile

Updated before January 2025

Company Overview

Becton, Dickinson and Company (BDX), commonly referred to as BD, is a global medical technology company that has been at the forefront of healthcare innovation for over a century. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson in East Rutherford, New Jersey, BD has grown into one of the largest and most respected companies in the medical technology sector. Headquartered in Franklin Lakes, New Jersey, BD operates in more than 190 countries and employs over 75,000 people worldwide. The company is led by Tom Polen, who serves as Chairman, Chief Executive Officer, and President. Under his leadership, BD continues to focus on advancing healthcare by improving medical discovery, diagnostics, and the delivery of care.

Core Business Segments

BD operates through three primary business segments, each offering a diverse range of products and services that cater to various aspects of healthcare:

1. BD Medical

This segment focuses on products and solutions that improve medication delivery and management. Key offerings include:

  • Medication Delivery Solutions: Syringes, needles, and IV catheters.
  • Pharmaceutical Systems: Prefillable drug delivery systems, including glass and plastic syringes.
  • Diabetes Care: Insulin syringes, pen needles, and other diabetes management tools.

2. BD Life Sciences

This segment is dedicated to advancing the world of diagnostics and research. Key offerings include:

  • Integrated Diagnostic Solutions: Instruments and reagents for clinical diagnostics, including blood collection systems and microbiology solutions.
  • Biosciences: Flow cytometry instruments, reagents, and software for cell analysis and research.

3. BD Interventional

This segment focuses on minimally invasive surgical and interventional procedures. Key offerings include:

  • Peripheral Intervention: Devices for vascular access and peripheral vascular disease treatment.
  • Surgery: Advanced surgical instruments and infection prevention products.
  • Urology and Critical Care: Catheters, drainage systems, and other urological solutions.

Business Model

BD’s business model revolves around integrating innovative products and services to address critical healthcare needs. The company generates revenue through the sale of medical devices, diagnostic instruments, and consumables. BD also offers value-added services such as training, technical support, and consulting to healthcare providers. By leveraging its global manufacturing and distribution network, BD ensures the availability of its products in both developed and emerging markets. The company’s focus on research and development (R&D) enables it to continuously innovate and maintain a competitive edge.

Strategic Direction

BD is committed to driving growth through innovation, sustainability, and global expansion. Key strategic priorities include:

  • Innovation: Investing in R&D to develop new products and technologies, particularly in areas like molecular diagnostics, smart drug delivery systems, and advanced surgical tools.
  • Sustainability: Setting ambitious environmental goals, such as reducing greenhouse gas emissions and minimizing waste. BD aims to achieve carbon neutrality in its operations by 2040.
  • Global Expansion: Strengthening its presence in emerging markets by tailoring products and solutions to local needs.
  • Digital Transformation: Leveraging data analytics and digital technologies to enhance product performance and improve patient outcomes.

Competitive Landscape

BD operates in a highly competitive industry, facing competition from both large multinational corporations and smaller specialized companies. Key competitors include:

  • Medtronic: A leader in medical devices and therapies.
  • Thermo Fisher Scientific: A major player in life sciences and diagnostics.
  • Abbott Laboratories: Known for its diagnostic and medical device offerings.
  • Johnson & Johnson: A diversified healthcare company with a strong presence in medical devices and diagnostics.
  • Roche Diagnostics: A leader in in-vitro diagnostics and laboratory solutions.

Despite the competition, BD’s extensive product portfolio, strong brand reputation, and focus on innovation give it a significant competitive advantage.

Risk Factors

Like any global company, BD faces several risks that could impact its operations and financial performance. Key risks include:

  • Market Dependence: Reliance on the sale of medical devices and consumables, which are subject to pricing pressures and regulatory changes.
  • Supply Chain Disruptions: Vulnerability to disruptions in the supply chain, particularly for raw materials and components.
  • Regulatory Compliance: The need to comply with stringent healthcare regulations in multiple countries.
  • Economic Conditions: Exposure to economic downturns, which can affect healthcare spending.
  • Cybersecurity Threats: Risks associated with data breaches and cyberattacks, particularly as BD adopts more digital technologies.

Recent Developments

BD has made significant strides in recent years, including:

  • COVID-19 Response: Developing diagnostic tests and supporting vaccine delivery efforts during the pandemic.
  • Acquisitions: Acquiring companies like C.R. Bard and CareFusion to expand its product portfolio and market reach.
  • Product Innovations: Launching new products such as the BD Veritor™ Plus System for rapid diagnostics and the BD Nano™ 2nd Gen pen needle for diabetes care.
  • Sustainability Initiatives: Implementing programs to reduce environmental impact, such as transitioning to renewable energy sources.

Investment Considerations

BD offers several strengths and risks for potential investors to consider:

Strengths:

  • Diverse Product Portfolio: A wide range of products and services that cater to various healthcare needs.
  • Global Presence: Operations in over 190 countries, providing access to both developed and emerging markets.
  • Strong R&D Focus: Continuous investment in innovation to maintain a competitive edge.
  • Resilient Business Model: Steady demand for medical devices and consumables, even during economic downturns.

Risks:

  • Regulatory Challenges: Compliance with complex and evolving healthcare regulations.
  • Market Competition: Intense competition from other medical technology companies.
  • Economic Sensitivity: Exposure to changes in healthcare spending and economic conditions.

Conclusion

Becton, Dickinson and Company (BDX) is a global leader in medical technology, with a rich history of innovation and a strong commitment to improving healthcare outcomes. With its diverse product portfolio, global reach, and focus on sustainability, BD is well-positioned for future growth. However, the company must navigate challenges such as regulatory compliance, market competition, and supply chain risks. Overall, BD remains a compelling choice for investors seeking exposure to the healthcare sector, given its resilience and growth potential.